Preprint Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates, 2024, Naninck et al.

Discussion in 'Long Covid research' started by SNT Gatchaman, Oct 28, 2024.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,923
    Location:
    Aotearoa New Zealand
    Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates
    Thibaut Naninck; Alexandra Detrille; Steve Huvelle; Marit J. van Gils; Tatiana Geara; Quentin Pascal; Jonne Snitselaar; Laetitia Bossevot; Mariangela Cavarelli; Nathalie Bosquet; Francis Relouzat; Vanessa Contreras; Catherine Chapon; Fabien Caillé; Rogier Sanders; Roger Le Grand

    The COVID-19 pandemic has caused nearly 780 million cases globally. While available treatments and vaccines have allowed a reduction of the mortality rate, the spread of the virus is still evolving quickly, resulting in the emergence of new variants. Despite extensive research, the long-term impact of SARS-CoV-2 infection is still poorly understood and requires further investigation.

    Routine analysis provides limited access to the tissues of patients, necessitating alternative approaches to investigate viral dissemination in the organism. We addressed this issue by implementing a whole-body in vivo imaging strategy to longitudinally assess the biodistribution of SARS-CoV-2. We demonstrate in a COVID-19 non-human primate model that a single injection of non-neutralizing radiolabeled [89Zr]COVA1-27-DFO human monoclonal antibody targeting a preserved epitope of the SARS-CoV-2 spike protein allows longitudinal tracking of the virus by positron emission tomography with computed tomography (PET/CT).

    Convalescent animals exhibited a persistent [89Zr]COVA1-27-DFO PET signal in the lungs, as well as in the brain, three months following infection. This imaging approach also allowed detection of the virus in various organs, including the airways and kidneys, of exposed animals during the acute phase of infection.

    Overall, the technology we developed offers a comprehensive assessment of SARS-CoV-2 distribution in vivo and provides a new approach for the non-invasive study of long-COVID physiopathology.

    Link | PDF (Preprint: Research Square) [Open Access]
     
    Last edited: Nov 4, 2024
  2. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,923
    Location:
    Aotearoa New Zealand
    Study in non-human primates, following on from SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells (2023, Nature Immunology)

     
    Last edited: Nov 1, 2024
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,697
    Location:
    Aotearoa New Zealand
    Paris/Amsterdam study

    I think the importance of the study is not in showing that the CoV-2 antigens persist (as that has been done before), but that these researchers have a way of tracking their presence non-invasively in living animals. It might also be in demonstrating again that the antigens are getting into the brain - I'm not quite sure about that (see below).

    They checked their imaging results by necroscopies.

    They injected their tracer into monkeys 3 months after a CoV-2 infection and found persisting antigens. They also tracked the evolution of CoV-2 infections. They used a control radioactive tracer (no affinity for the CoV-2 antigen), and control monkeys (no infection).

    I thought this was interesting about a kidney stone and the presence of the virus RNA in the kidneys:
    They tried a lower dose of the radioactive tracer and didn't get useful results. (Something to bear in mind for studies like these.)

    Re the brain findings - this is in the animals 3 months after infection (they didn't find the antigen in the brains of the animals with the acute infection)
    But have a look at figures 3h and 3i. There was no difference in the mean signals of the tracer in the convalescent and controls animals and they comment that the mean levels were low in all the animals. (Also, only two animals of each, which is understandable, given these are monkeys.) But there was a difference in the max values - so that's the 'local', in 'we also detected local accumulation of the radio tracer in areas of the brain'. So, it seemed to be just specific bits of the brain lighting up. They don't say what bits of the brain showed the signal.
     
    Last edited: Oct 28, 2024
    shak8, RedFox, Nightsong and 6 others like this.
  4. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,697
    Location:
    Aotearoa New Zealand
    Just as an aside, I started reading 'Whole-body visualisation' and braced myself for what was to come. I wonder if you can get PTSD from constant exposure to BPS research?
     
    shak8, Dolphin, RedFox and 7 others like this.
  5. alktipping

    alktipping Senior Member (Voting Rights)

    Messages:
    1,301
    Not PTSD just a high alert for bullshit because we have had to wade through so much .
     
  6. Dolphin

    Dolphin Senior Member (Voting Rights)

    Messages:
    5,884
    Link doesn’t seem to be unique while pdf is https://assets-eu.researchsquare.co...-f525-43be-889a-027b8bba5975.pdf?c=1729649111
    Weekly bulletin uses non-unique link.
     
    SNT Gatchaman and Peter Trewhitt like this.
  7. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,923
    Location:
    Aotearoa New Zealand
    Drats, I missed that error — thank you for pointing out. Research Square has incorrect metadata in its header. I've corrected this thread and asked for the News item to be corrected too.
     

Share This Page